[HTML][HTML] Molecular mechanisms of ferroptosis and their involvement in brain diseases

I Costa, DJ Barbosa, S Benfeito, V Silva… - Pharmacology & …, 2023 - Elsevier
Ferroptosis is a type of regulated cell death characterized by intracellular accumulation of
iron and reactive oxygen species, inhibition of system Xc-, glutathione depletion …

Modeling Parkinson's disease with the alpha-synuclein protein

M Gómez-Benito, N Granado, P García-Sanz… - Frontiers in …, 2020 - frontiersin.org
Alpha-synuclein (α-Syn) is a key protein involved in Parkinson's disease (PD) pathology. PD
is characterized by the loss of dopaminergic neuronal cells in the substantia nigra pars …

α-Synuclein aggregation nucleates through liquid–liquid phase separation

S Ray, N Singh, R Kumar, K Patel, S Pandey, D Datta… - Nature …, 2020 - nature.com
Abstract α-Synuclein (α-Syn) aggregation and amyloid formation is directly linked with
Parkinson's disease pathogenesis. However, the early events involved in this process …

α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis

S Mehra, S Sahay, SK Maji - Biochimica et Biophysica Acta (BBA)-Proteins …, 2019 - Elsevier
Abstract α-Synuclein (α-Syn) has been extensively studied for its structural and biophysical
properties owing to its pathophysiological role in Parkinson's disease (PD). Lewy bodies …

Liquid-liquid phase separation of α-synuclein: a new mechanistic insight for α-synuclein aggregation associated with Parkinson's disease pathogenesis

S Mukherjee, A Sakunthala, L Gadhe… - Journal of molecular …, 2023 - Elsevier
Aberrant aggregation of the misfolded presynaptic protein, α-Synuclein (α-Syn) into Lewy
body (LB) and Lewy neuritis (LN) is a major pathological hallmark of Parkinson's disease …

Tau accelerates α-synuclein aggregation and spreading in Parkinson's disease

L Pan, C Li, L Meng, Y Tian, M He, X Yuan, G Zhang… - Brain, 2022 - academic.oup.com
The aggregation and prion-like propagation of α-synuclein are involved in the pathogenesis
of Parkinson's disease. However, the underlying mechanisms regulating the assembly and …

Therapeutics in the pipeline targeting α-synuclein for Parkinson's disease

HG Jasutkar, SE Oh, MM Mouradian - Pharmacological reviews, 2022 - ASPET
Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …

Targeted degradation of⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology

J Lee, KW Sung, EJ Bae, D Yoon, D Kim… - Molecular …, 2023 - Springer
Background There are currently no disease-modifying therapeutics for Parkinson's disease
(PD). Although extensive efforts were undertaken to develop therapeutic approaches to …

Tau in the pathophysiology of Parkinson's disease

L Pan, L Meng, M He, Z Zhang - Journal of Molecular Neuroscience, 2021 - Springer
The pathological hallmarks of Parkinson's disease (PD) are the progressive loss of
dopaminergic neurons in the substantia nigra and the formation of Lewy bodies (LBs) in …

Structural and functional insights into α-synuclein fibril polymorphism

S Mehra, L Gadhe, R Bera, AS Sawner, SK Maji - Biomolecules, 2021 - mdpi.com
Abnormal accumulation of aggregated α-synuclein (α-Syn) is seen in a variety of
neurodegenerative diseases, including Parkinson's disease (PD), multiple system atrophy …